Satralizumab

Names

[ Name ]:
Satralizumab

Biological Activity

[Description]:

Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

IL-6

[In Vivo]

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus[1]. Animal Model: Rattus norvegicus (forty, male, 10-week-old, four equal groups)[1] Dosage: 120 mg Administration: Subcutaneously, once every 2 weeks, for 4 weeks Result: Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.

[References]

[1]. Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26.

[2]. Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11(1):49-59.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.